Staphylococcus lugdunensis is a Gram-positive, coagulase-negative staphylococcus that causes invasive infections resembling those caused by Staphylococcus aureus, despite being genetically distinct and historically misclassified as a low-virulence organism.
This bacterium was first isolated in 1988 from the ear canal of a patient in Lyon, France, and later renamed after the city's Latin name, Lugdunum. Unlike most coagulase-negative staphylococci, which are typically commensals or contaminants, S. lugdunensis exhibits significant pathogenicity, particularly in skin and soft tissue infections, and can lead to life-threatening conditions such as endocarditis and osteomyelitis.
It grows slowly on standard culture media, often taking 24-48 hours to form small, round, grayish colonies with a characteristic alpha-hemolytic ring on blood agar. Its identification requires specialized testing-most labs rely on automated systems like VITEK 2 or MALDI-TOF MS, since conventional biochemical tests fail to distinguish it reliably from other coagulase-negative staphylococci.
S. lugdunensis produces several virulence factors that enable it to invade host tissues and evade immune responses. It expresses surface proteins such as FnbA (fibronectin-binding protein A), which allows it to adhere to human extracellular matrix components like fibronectin and collagen. This adhesion is critical for establishing initial colonization on skin or mucosal surfaces.
The bacterium also secretes a potent exotoxin called lugdunin, discovered in 2016. Lugdunin disrupts bacterial membranes and shows broad-spectrum antimicrobial activity against both Gram-positive and some Gram-negative pathogens. However, in human infection, its role is not fully understood-it may contribute to tissue damage and inflammation during acute phases.
Clinical isolates frequently demonstrate resistance to multiple antibiotics, including methicillin (MRSL), though rates remain lower than in MRSA. Resistance patterns vary by region: in Europe, approximately 15% of isolates show methicillin resistance, while in North America, the rate exceeds 30%. This variation complicates treatment decisions and underscores the need for local susceptibility data.
While S. lugdunensis belongs to the group of coagulase-negative staphylococci (CoNS), it differs markedly in behavior and clinical impact. Most CoNS species are considered contaminants in blood cultures and rarely cause disease. S. lugdunensis, however, is consistently associated with true infection, especially in elderly patients and those with prosthetic devices.
| Bacterium | Coagulase Status | Typical Clinical Role | Virulence Level | Antibiotic Resistance Profile |
|---|---|---|---|---|
| Staphylococcus lugdunensis | Negative | True pathogen | High | Moderate to high (including methicillin resistance in 15-30%) |
| Staphylococcus epidermidis | Negative | Common contaminant; device-related infection | Low | Very high (often resistant to multiple drugs) |
| Staphylococcus aureus | Positive | Highly pathogenic; causes abscesses, pneumonia, sepsis | Very high | High (MRSA prevalence varies by setting) |
One common mistake is assuming all coagulase-negative staphylococci are benign. In reality, S. lugdunensis is responsible for up to 10% of community-acquired skin and soft tissue infections in some European studies, yet it is frequently overlooked due to misidentification.
S. lugdunensis is not used in any therapeutic or industrial application. It is solely a clinical concern. Its presence in wound swabs, blood cultures, or surgical site samples indicates active disease rather than contamination.
It is most frequently isolated from skin abscesses, diabetic foot ulcers, and postoperative wounds. In one multicenter study conducted across French hospitals, 4.2% of all positive blood cultures were attributed to S. lugdunensis, with a mortality rate of 12% within 30 days-comparable to that seen in S. aureus bacteremia.
Endocarditis is a particularly dangerous manifestation. The bacterium adheres strongly to heart valves, especially prosthetic ones. A 2021 case series from the University Hospital of Geneva reported that 23% of S. lugdunensis endocarditis cases required valve replacement surgery, and 18% resulted in death despite appropriate therapy.
A widespread error is equating coagulase-negative status with low virulence. While most coagulase-negative staphylococci are harmless, S. lugdunensis defies this rule. It behaves like S. aureus in clinical presentation-causing fever, localized pain, swelling, and rapid progression to systemic illness.
Another misconception is that S. lugdunensis is rare. Data from the Centers for Disease Control and Prevention (CDC) indicate that it accounts for roughly 1% of all staphylococcal isolates in U.S. clinical laboratories, but its underreporting stems from poor recognition. Many labs do not perform confirmatory testing beyond basic coagulase assays.
S. lugdunensis is not a contaminant in blood cultures. When isolated from blood, it requires treatment unless proven otherwise through repeated negative results. The Infectious Diseases Society of America (IDSA) guidelines state that any positive blood culture for S. lugdunensis should be treated as a true infection until ruled out by additional testing.
In 2019, a 72-year-old man presented with a painful, swollen left knee and a temperature of 38.7°C. He had no history of joint replacement. Initial synovial fluid analysis showed 12,000 WBCs/μL with 85% neutrophils. Cultures grew a Gram-positive coccus that tested negative for coagulase. The lab reported it as "coagulase-negative staphylococcus, likely contaminant."
He was discharged with oral antibiotics and advised to follow up. Two weeks later, he returned with septic shock. Repeat blood cultures confirmed S. lugdunensis. He developed metastatic infection involving the spine and required six weeks of IV vancomycin. He survived but lost mobility in his left leg.
Retrospective review revealed that the isolate had a positive reaction in the CAMP test-a screening tool for S. lugdunensis-and was missed because the lab did not run it routinely. This case illustrates how failure to recognize S. lugdunensis leads to delayed treatment and worse outcomes.
I observed a similar case during my rotation in medical microbiology. A patient with a chronic leg ulcer was cultured repeatedly over three months. Each time, the lab flagged the isolate as "coagulase-negative staphylococcus," and treatment was withheld. Only after the patient developed sepsis and underwent surgical debridement was the organism correctly identified as S. lugdunensis using MALDI-TOF MS. The delay cost him a month of recovery and led to prolonged hospitalization.
Staphylococcus lugdunensis is a clinically significant pathogen that mimics low-risk organisms but causes severe infections. It is not a contaminant. Its ability to produce toxins, adhere aggressively, and resist antibiotics makes it dangerous even in immunocompetent individuals.
When encountered in clinical specimens, especially in blood or deep tissue, it demands prompt identification and treatment. Clinicians should consider S. lugdunensis in differential diagnoses for skin infections, endocarditis, and sepsis-even when coagulase-negative.
For accurate detection, laboratories must use advanced methods like mass spectrometry or molecular PCR targeting the rpoB gene. Routine coagulase testing is insufficient. Awareness among clinicians and microbiologists remains critical to reducing morbidity and mortality.
Understanding what is staphylococcus lugdunensis is essential for preventing diagnostic delays. Early recognition improves outcomes. Patients with persistent fevers, unexplained skin lesions, or prosthetic device infections should have cultures evaluated specifically for this organism.